Erik Lium

CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre.

Accelerate Long Island/venture capital/ (Accelerate Long Island (Venture Capital)) is a venture capital firm, a subsidiary of Accelerate Long Island, Inc founded in 2016. The firm is headquartered in Melville, New York.

PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021.

The Mount Sinai Health System, Inc. provides health care system services. It is an integrated health care system providing exceptional medical care to our local and global communities. The company is headquartered in New York, NY.

Kantaro Biosciences LLC is a health system venture that provides high-quality diagnostic tests for critical health challenges. The joint venture company is based in New York, NY. The company is dedicated to advancing the care and well-being of people, communities, and society by offering rigorous, results-driven, and reproducible diagnostics. Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market.